



CLÍNICA E INVESTIGACIÓN EN ARTERIOSCLEROSIS

www.elsevier.es/arterio



CLINICAL REPORT

Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia



Francesco Sbrana*, Beatrice Dal Pino, Federico Bigazzi, Tiziana Sampietro

Lipoapheresis Unit – Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana “Gabriele Monasterio”, Via Moruzzi 1, Pisa 56124, Italy

Received 11 October 2023; accepted 2 November 2023

Available online 27 de noviembre de 2023

KEYWORDS

Cutaneous xanthomas;
Heterozygous familial hypercholesterolemia;
Lipid lowering therapy;
Tendon xanthomas;
Xanthelasma

Abstract “The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412 mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas.

© 2023 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE

Xantomas cutáneos;
Hipercolesterolemia familiar heterocigótica;
Terapia hipolipemiente;
Xantomas tendinosos;
Xantelasma

Regresión generalizada de xantomas mediante terapia hipolipemiente personalizada en hipercolesterolemia familiar heterocigótica

Resumen «Cuanto más bajo, mejor» es el enfoque recomendado en el tratamiento del colesterol LDL alto. Lamentablemente esto no siempre se logra como en el caso de una mujer de 69 años remitida a nuestro Instituto por su perfil lipídico (colesterol LDL 412 mg/dL), xantelasma bilateral y xantomas cutáneos. Con terapias hipolipemientes maximizadas y personalizadas (rosuvastatina, ezetimiba, iPCSK9 y aféresis de lipoproteínas), después de solo seis meses, la paciente mostró una regresión impresionante en sus xantomas cutáneos.

© 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

* Corresponding author.

E-mail address: francesco.sbrana@ftgm.it (F. Sbrana).

Familial hypercholesterolemia (FH) is a genetic disease causing severe and premature atherosclerotic cardiovascular disease. “The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve¹ as in the case of a 69-year-old woman referred to our Institute for her lipid profile [LDL-C 412 mg/dl, Lp(a) 119 mg/dl], bilateral xanthelasma and cutaneous xanthomas (Fig. 1 Panels A and B). At the age of 47, she undergone to PTCA/stenting on left anterior descending artery for effort angina. In the following twenty-two years, the patient did not experience any further cardiac event while self-discontinuing lipid-lowering therapies (LLT).

The physical examination was positive for Achilles tendon xanthomas (Fig. 2); CT coronary angiography showed diffuse non-critical calcific atherosclerotic disease and a 40% stenosis at the carotid bulb bilaterally was revealed. Genetic test confirmed the diagnosis of heterozygous familial hypercholesterolemia (HeFH). LLT with rosuvastatin/ezetimibe (20/10 mg OD), evolocumab (140 mg s.c. every 14 days) and lipoprotein apheresis (LA) was started (Liposorber®-LA MA-03 systems; Kaneka, Osaka, Japan) achieving a median inter-aphaeretic concentration of LDL-C and Lp(a) of 34 mg/dl and 40 mg/dl respectively.

With this maximized LLT, after six months, the patient showed an impressive regression in her cutaneous xanthomas (Fig. 1 Panels C and D).

Patients with HeFH with elevated lipoprotein(a) and previous cardiovascular events represent a comorbidity profile hard to manage and the current guidelines propose a more aggressive lowering in LDL-C and cholesterol-rich apolipoprotein B for their key role in the arterial wall atherogenesis.¹

The singularity of the described case is represented by over-time stability of atherosclerotic disease in contrast of the widespread lipid deposits in the skin and tendons, even in the absence of LLT. The personalization of LLT becomes fundamental especially in patients affected by heterozygous FH and high Lp(a) in the light of their high cardiovascular risk.

FH patients are often characterized by age-related fat deposition on the Achilles tendon, showing thickening and




Figure 2 Panel A – Physical examination of Achilles tendon xanthomas (arrowhead). Panel B – Achilles tendon ultrasonography with increased thickness and irregular hypoechoic region (circle).

fragility, and also related with the severity of coronary artery disease.^{2,3} We know that short-term evolocumab is able to induce tendon xanthomas regression in a patient with homozygous FH,⁴ that in HeFH the addition of a PCSK9 inhibitor to backbone LLT resulted in tendon xanthomas regression after 3 years of treatment⁵ and that LA treatment allows the complete regression of lipid deposition⁶ because accelerate the efficacy of LLT. In this case we combined all these therapies to maximize their effect.

Waiting for the new drugs on the way, as the antisense oligonucleotides against apolipoprotein (a), the first step is the personalization of the therapy safeguarding heterozygous FH patient's safety and quality of life, keeping in mind




Figure 1 Baseline bilateral xanthelasma (Panel A) and extensive cutaneous xanthomas localized at the trunk (Panel B). Partial regression in xanthelasma (Panel C) and in cutaneous xanthomas hyperpigmentation (Panel D) obtained after six months of maximal lipid lowering therapy (rosuvastatin/ezetimibe 20/10 mg OD + evolocumab 140 mg s.c. every 14 days + lipoprotein apheresis).

that the correct diagnosis¹ and therapeutic adherence⁷ are essential stages for patient's clinical management.

Authors' contribution

FS, BDP, FB and TS: contributed to conception or design, drafted and critically revised the manuscript. All authors read and approved the final version of the manuscript.

Authors' approval

All authors have seen and approved the study submitted. No part of the submitted work has been published or is under consideration for publication elsewhere.

Notes

Data have not been presented at any congress.

Consent for publication

The patient signed the informed consent form for anonymous medical data usage in our paper.

Funding sources

No financial support was received.

Conflict of interest

No conflict of interest for each author.

Acknowledgements

None.

References

1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41:111–88.
2. Hamaguchi H. Can Achilles tendon assessment of adult familial hypercholesterolemia be reflected as a risk factor for arteriosclerosis? *J Atheroscler Thromb*. 2022;29:1568–70.
3. Kitahara H, Nakayama T, Fujimoto Y, Kobayashi Y. Association between Achilles tendon xanthoma and severity of coronary artery disease in patients undergoing percutaneous coronary intervention. *J Cardiol*. 2020;75:654–8.
4. Cicero AFG, Fogacci F, Bragagni A, Borghi C. Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia. *Intern Emerg Med*. 2023;18:307–10.
5. Bea AM, Perez-Calaborra S, Marco-Benedi V, Lamiquiz-Moneo I, Jarauta E, Mateo-Gallego R, et al. Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia. *Atherosclerosis*. 2017;263:92–6.
6. Sampietro T, Sbrana F, Bigazzi F, Ripoli A, Dal Pino B. Null receptor homozygous familial hypercholesterolaemia: quoad valetudinem long life treatment. *Eur J Prev Cardiol*. 2020;27:2105–8.
7. Dal Pino B, Sbrana F. Therapeutic adherence in hyperlipidemia: when one size doesn't fit all. *Eur J Intern Med*. 2023;112:143–5.